Selecta Biosciences Inc (NASDAQ:SELB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm presently has a $15.00 price target on the stock. Zacks Investment Research’s price target indicates a potential upside of 3.95% from the company’s current price.

According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “

Other equities research analysts also recently issued research reports about the company. Needham & Company LLC initiated coverage on Selecta Biosciences in a report on Monday, July 18th. They set a “buy” rating and a $28.00 price objective on the stock. Canaccord Genuity initiated coverage on Selecta Biosciences in a report on Monday, July 18th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on Selecta Biosciences in a report on Monday, July 18th. They set a “buy” rating and a $23.00 price objective on the stock.

Shares of Selecta Biosciences (NASDAQ:SELB) opened at 14.43 on Tuesday. Selecta Biosciences has a one year low of $10.26 and a one year high of $16.32. The firm has a 50 day moving average price of $12.46 and a 200 day moving average price of $12.91.

In other Selecta Biosciences news, major shareholder Nanodimension Management Ltd acquired 385,000 shares of the stock in a transaction dated Monday, June 27th. The stock was purchased at an average cost of $14.00 per share, with a total value of $5,390,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Amir Nashat acquired 150,000 shares of the stock in a transaction dated Monday, June 27th. The stock was acquired at an average cost of $14.00 per share, with a total value of $2,100,000.00. The disclosure for this purchase can be found here.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Polaris Venture Management Co. V L.L.C. acquired a new position in Selecta Biosciences during the second quarter valued at $26,919,000. Perceptive Advisors LLC acquired a new position in Selecta Biosciences during the second quarter valued at $6,296,000. JPMorgan Chase & Co. acquired a new position in Selecta Biosciences during the second quarter valued at $4,215,000. FMR LLC acquired a new position in Selecta Biosciences during the second quarter valued at $3,997,000. Finally, Vanguard Group Inc. acquired a new position in Selecta Biosciences during the second quarter valued at $1,679,000.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

5 Day Chart for NASDAQ:SELB

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Selecta Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.